ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

News

Media Releases

General Standby Statement

July 1st, 2020|

Agendia, Inc. has entered into a Settlement Agreement with the U.S. Department of Justice (DOJ) acting on behalf of the Office of Inspector General of the Department of Health and Human Services (OIG-HHS) to resolve Read More

Agendia Announces Data Presented at ASCO 2020 Demonstrating Importance of Further Classification of Breast Cancers to Enable Precise Prognosis and Treatment

May 29th, 2020|

PRESS RELEASE Presentations outline how BluePrint​®​ genomic testing enables further categorization of HER2-positive cancer and reclassification of ER+ tumors for patients’ benefit FLEX registry reinforces the clinical and real-world utility of MammaPrint® and BluePrint to Read More